Long-term follow-up of orally administered diacetylmorphine substitution treatment

European Addiction Research

Volumn 16, Issue 3, 2010, Pages 131-138

  Frick, Ulrich ^a,b,c   Rehm, Jürgen ^a,d,e,f   Zullino, Daniele ^g   Fernando, Manrique ^h   Wiesbeck, Gerhard ⁱ   Ammann, Jeannine ^a   Uchtenhagen, Ambros ^a  

^a Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

^b CARINTHIA UNIVERSITY OF APPLIED SCIENCES   (Austria)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h Cantonal Drug Counselling   (Switzerland)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bias; Heroin substitution treatment; Open label study; Opioid dependence; Oral application; Prospective cohort

Indexed keywords

DIAMORPHINE;

ABSTINENCE; ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; TABLET; UNSPECIFIED SIDE EFFECT; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MEDICATION COMPLIANCE; OPIOID-RELATED DISORDERS; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ADULT; FEMALE; FOLLOW-UP STUDIES; HEROIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MEDICATION ADHERENCE; OPIOID-RELATED DISORDERS;

EID: 77951229155     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313335     Document Type: Article

References (24)

1. United Nations Office on Drugs and Crime: Principles of Drug Dependence Treatment. Geneva, WHO, 2008.
2. World Health Organization, United Nations Office on Drugs and Crime, UNAIDS: Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/ AIDS Prevention: Position Paper. Geneva, WHO, 2004.
3. Gonzalez G, Oliveto A, Kosten TR: Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 2004; 5: 713-725.
4. Uchtenhagen A: Substitution management in opioid dependence. J Neural Transm Suppl 2003; 66: 33-60.
5. Fischer B, Rehm J, Kim G, Kirst M: Eyes wide shut? a conceptual and empirical critique of methadone maintenance treatment (MMT). Eur Addict Res 2005; 11: 1-9.
6. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 385: 1417-1420.
7. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, Steffen T, Rihs-Middel M (eds): Prescription of Narcotics for Heroin Addicts - Main Results of the Swiss National Cohort Study. Basel, Karger, 1999, p 134.
8. Perneger TV, Giner F, del Rio M, Mino A: Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18.
9. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777-786.
10. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D: Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2007; 191: 55-62.
11. van den Brink W, Hendriks V, Blanken P, Koeter M, van Zwieten B, van Rhee JM: Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327: 310.
12. Kastelic A, Dubajic G, Strbad E: Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 2008; 103: 1837-1846.
13. Frick U, Gerlich M, Ammann J: Applikationsformen von Diacetylmorphin und unerwünschte Arzneimittelwirkungen: April 2001 bis Oktober 2003: Forschungsbericht aus dem Institut für Suchtforschung. Zürich, Institut für Suchtforschung, 2003.
14. Girardin F, Rentsch K, Schwab M, Maggiorini M, Pauli-Magnus C, Kullak-Ublick G, Meier P, Fattinger K: Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther 2003; 74: 341-352.
15. Perger L, Rentsch KM, Kullak-Ublick GA, Verotta D, Fattinger K: Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. Eur J Pharm Sci 2009; 36: 421-432.
16. Frick U, Rehm J, Kovacic S, Ammann J, Uchtenhagen A: A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 2006; 101: 1631-1639.
17. Gyr E, Bourquin D, Lehmann T, Hug I, Brenneisen R: Pharmacokinetics and pharmacodynamics of orally administered diacetylmorphine hydrochloride. J Anal Toxicol 1997; 21: 93.
18. Halbsguth U, Rentsch KM, Eich-Höchli D, Diterich I, Fattinger K: Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. Br J Clin Pharmacol 2008; 66: 781-791.
19. Bundesamt für Gesundheit B: Handbuch heroingestützte Behandlung. Richtlinien, Empfehlung, Information. Bern, Bundesamt für Gesundheit, 2000.
20. Frick U, Ammann J, Kovacic S, Bürki C, Mohler M, Käser R, Gerlich M, Güttinger F, Gschwend P, Rehm J: Qualitätssicherung in der Heroin gestützten Behandlung (HegeBe) der Schweiz seit 2001: Methodische Anmerkungen zu Zielkriterien, Adjustierung des Patienten-Mix und Zentrumsvergleichen. Gesundheitsökonomie & Qualitätsmanagement 2006; 11: 155-161.
21. Frick U, Güttinger F, Ammann J, Kovacic S, Rehm J, Uchtenhagen A: Kohortenstudie zur Erfassung der Sicherheit und Verträglichkeit von Diacetylmorphin in peroraler Verabreichung bei opioidabhängigen Probanden. Forschungsberichte aus dem Institut für Sucht-und Gesundheitsforschung. Zürich, Institut für Sucht-und Gesundheitsforschung, 2005.
22. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noël L, Tyndall MW, Wild CT, Mun P, Baliunas D: Illicit opioid use in Canada - comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005; 82: 250-266.
23. Fischer B, Rehm J, Patra J, Firestone-Cruz M: Changes in illicit opioid use profiles across Canada. Can Med Assoc J 2006; 75: 1385-1387.
24. Frick U, Ammann J, Rehm J, Uchtenhagen A: Diacetylmorphin in peroraler Verabreichung bei opioid-abhängigen Probanden: 2-Jahres Follow-up: Forschungsbericht aus dem Institut für Sucht-und Gesundheitsforschung. Zurich, Research Institute for Public Health and Addiction, 2007.